SIRPA and melanoma: conducted integrated transcriptomic and proteomic analysis of emerging immunooncology targets in melanoma across multiple clinical cohorts receiving anti-PD-1 therapy, finding that patients with tumors carrying high expression of signal regulatory protein alpha (SIRPA) exhibited favorable responses to anti-PD-1 immunotherapy.